U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H14ClN3O2S
Molecular Weight 371.841
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DENOTIVIR

SMILES

CC1=NSC(NC(=O)C2=CC=CC=C2)=C1C(=O)NC3=CC=C(Cl)C=C3

InChI

InChIKey=ZPBLNADJHWHOEP-UHFFFAOYSA-N
InChI=1S/C18H14ClN3O2S/c1-11-15(17(24)20-14-9-7-13(19)8-10-14)18(25-22-11)21-16(23)12-5-3-2-4-6-12/h2-10H,1H3,(H,20,24)(H,21,23)

HIDE SMILES / InChI

Description

Denotivir is an organic chemical compound with antiviral activity. In vitro antiviral activity of denotivir has been demonstrated against human HSV types 1 and 2, and varicella zoster virus (VZV). Clinical trials with vratizolin have given impressive results in the patients with local HSV infections and very good results in VZV infections. Genital herpes, a sexually transmitted HSV infection, whose incidence is increasing and whose treatment has never been adequate, appears to respond well to the treatment with vratizolin with very good results. Very good therapeutic results were also obtained by applying vratizolin to the patients with an ophthalmic HSV infection. Vratizolin exerted strong immunosuppressive actions. Vratizolin inhibited to some degree LPS-induced cytokine production in human peripheral blood cultures. The activities of TNF-alpha, IL-1 and IL-6 were inhibited on average by 37, 26 and 35%, respectively.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

PubMed

Sample Use Guides

In Vivo Use Guide
2 to 3 times per day for 5 days.
Route of Administration: Topical